Mechanistic Prediction of Maternal, Fetal, and Amniotic Fluid Betamethasone Concentrations to Support Dosing Optimization in Pregnancy
The Journal of Clinical Pharmacology · 2026-10 · 66 (10)
DOI: 10.1002/jcph.70308 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 14.10.2026. Verfasst von Alaa Mahdi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA. Hauptthemen laut MEDLINE: Betamethasone, Amniotic Fluid, Glucocorticoids, Models, Biological. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health.
Abstract (Originalsprache)
Respiratory distress syndrome (RDS) remains a major cause of neonatal mortality following premature birth. Antenatal betamethasone is the standard of care to accelerate fetal lung maturation and improve neonatal outcomes; however, current dosing recommendations assume uniform maternal and fetal exposure across pregnancies. Gestational age (GA)‐dependent physiological changes and maternal obesity may alter betamethasone disposition and fetal exposure. This study developed a maternal–fetal physiologically based pharmacokinetic (m‐f‐PBPK) model to quantify the effects of GA and maternal obesity on betamethasone exposure and evaluate current dosing recommendations between 24 and 34 gestational weeks. The m‐f‐PBPK model incorporated maternal CYP3A‐mediated metabolism, placental passive diffusion and active efflux via P‐glycoprotein (P‐gp), placental metabolic clearance, GA‐dependent physiology, and formulation‐specific release rates of betamethasone phosphate and acetate. Model performance was evaluated using maternal and fetal exposure metrics across gestation. At GA 30 weeks in non‐obese pregnancies, placental metabolic clearance contributed approximately 17% of maternal clearance, whereas fetal hepatic metabolism accounted for only 2.4%. Maternal obesity decreased maternal and fetal exposure by approximately 9%, while morbid obesity reduced exposure by 23%. Simulated fetal concentrations remained above the proposed pre‐clinical‐derived surrogate marker of 2 ng/mL for a median duration of 38‐40 h in non‐obese, 37.5‐39 h in obese, and 30‐32 h in morbidly obese populations. This m‐f‐PBPK model successfully characterized maternal–fetal pharmacokinetics and provides a mechanistic basis for understanding betamethasone fetal exposure across GAs with and without maternal obesity, supporting optimization of antenatal corticosteroid therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA.
- Simcyp Division, Certara, Sheffield, UK.
- Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
- Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil.
- School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
ORCID-Profile: Alaa Mahdi, Khaled Abduljalil, Fernanda de Lima Moreira, Hiral Raju Mehta, Jhohann Richard de Lima Benzi, Stephan Schmidt, Natalia V de Moraes
Förderung
- NICHD NIH HHS
- the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health
Zitieren
APA
Mahdi, A., Abduljalil, K., Moreira, F. L., Mehta, H. R., Benzi, J. R. L., Marcolin, A. C., Schmidt, S., & de Moraes, N. V. (2026). Mechanistic Prediction of Maternal, Fetal, and Amniotic Fluid Betamethasone Concentrations to Support Dosing Optimization in Pregnancy. The Journal of Clinical Pharmacology, 66(10). https://doi.org/10.1002/jcph.70308
Vancouver
Mahdi A, Abduljalil K, Moreira FL, Mehta HR, Benzi JRL, Marcolin AC, et al. Mechanistic Prediction of Maternal, Fetal, and Amniotic Fluid Betamethasone Concentrations to Support Dosing Optimization in Pregnancy. The Journal of Clinical Pharmacology. 2026;66(10). doi:10.1002/jcph.70308
BibTeX
@article{Mahdi2026,
author = {Mahdi, Alaa and Abduljalil, Khaled and Moreira, Fernanda de Lima and Mehta, Hiral Raju and Benzi, Jhohann Richard de Lima and Marcolin, Alessandra Cristina and Schmidt, Stephan and de Moraes, Natalia V},
title = {Mechanistic Prediction of Maternal, Fetal, and Amniotic Fluid Betamethasone Concentrations to Support Dosing Optimization in Pregnancy},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {10},
doi = {10.1002/jcph.70308}
}
EUVIMED